Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05992324 · ClinicalTrials.gov registry record · NA

A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation

A NA study of Shortness of Breath, sponsored by Caption Health.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
4
Study locations

NCT05992324: Recruiting NA study of Shortness of Breath, sponsored by Caption Health.

NCT05992324 is a NA study of Shortness of Breath that is actively recruiting participants, run by Caption Health. The registered enrollment target is 220 participants, above the 64-participant average among 6 other Shortness of Breath trials with a reported enrollment target (244% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05992324, a NA study of Shortness of Breath, is actively recruiting participants, sponsored by Caption Health.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to assess the efficacy of Caption LungAI.

Primary Outcome

Evaluate the product's ability to assist the user to capture a LUS image with diagnostic quality. Percentage of zones with diagnostic image quality \> 0.80

Conditions Studied

Interventions

  • DEVICE Caption LungAI

Study Locations (4)

Illinois

  • Northwestern University - Chicago
  • Rush University Medical Center - Chicago

Connecticut

  • Yale New Haven Hospital - New Haven

North Carolina

  • The Moses H. Cone Memorial Hospital - Greensboro

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2023-07-17
Est. Completion 2025-03-01
Phase NA
Caption Health

3 total trials

What NCT05992324 shows while recruiting

NCT05992324 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 6 other Shortness of Breath trials with a reported enrollment target (244% higher).

The record links to 1 condition, with Shortness of Breath appearing as the primary indexed condition, and to 1 intervention - of which Caption LungAI is the first listed.

NCT05992324 reports a single indexed study location in Illinois, Connecticut, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05992324 about?

NCT05992324 is a clinical study titled "A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation". The purpose of this study is to assess the efficacy of Caption LungAI.

What is the current status of trial NCT05992324?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-07-17. Estimated completion is 2025-03-01.

What conditions does trial NCT05992324 study?

This clinical trial studies the following conditions: Shortness of Breath.

What interventions are being tested in trial NCT05992324?

The interventions under investigation include: Caption LungAI (DEVICE).

Who is sponsoring clinical trial NCT05992324?

This trial is sponsored by Caption Health, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05992324 being conducted?

This trial has 4 study locations across Connecticut, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Shortness of Breath

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05992324, the US trial registry maintained by the National Library of Medicine. NCT05992324 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.